Errors in Figure 2 and Table 2 Footnotes

No authors listed

Published Erratum

No authors listed. JAMA Dermatol. 2023.

. 2023 Sep 1;159(9):1014.

doi: 10.1001/jamadermatol.2023.2199.

No abstract available

Erratum for

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, Ferrucci S, Lima RG, Witte MM, Xu W, ElMaraghy H, Natalie CR, Pierce E, Blauvelt A; ADhere Investigators. Simpson EL, et al. JAMA Dermatol. 2023 Feb 1;159(2):182-191. doi: 10.1001/jamadermatol.2022.5534. JAMA Dermatol. 2023. PMID: 36630140 Free PMC article. Clinical Trial.

1. Simpson EL, Gooderham M, Wollenberg A, et al. ; ADhere Investigators . Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol. 2023;159(2):182-191. doi: 10.1001/jamadermatol.2022.5534 - DOI - PMC - PubMed